Malaysia
Search
Sign In
Pharmacy
Top Medical News
In neonates who have asymptomatic hypoglycaemia in the first 48 hours of life, administering dextrose gel is useful and minimizes requirement for intravenous fluids, as shown in a study.
Infection with the omicron variant of SARS-CoV-2 was less likely to result in hospitalization than infection with the delta variant, according to an observational study from Denmark presented at ECCMID 2022 and published in The Lancet.
Following nonvalvular atrial fibrillation (NVAF)-associated stroke events, a graded increase in delay in direct oral anticoagulants (DOACs) initiation of between 1 and 4 days, depending on the severity of the index event, appears to be effective for recurrent stroke prevention and does not compromise safety both in Asians and Europeans, according to a recent study.
The addition of antitumour necrosis factor-alpha (anti-TNF-α) to steroid treatment may help improve outcomes for patients with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), suggest the results of a recent study.
For patients on glucocorticoid therapy, a delay in anti-osteoporosis treatment initiation may lead to increased fracture events, while early treatment helps to prevent them, a study has found.
A recent meta-analysis offers new proof of different canagliflozin doses for hypertension management in patients with type 2 diabetes mellitus (T2DM) complicated by hypertension. However, low-density lipoprotein cholesterol (LDL-C) and the risk of urinary tract infection must be observed.
In acute coronary syndrome (ACS) patients who have undergone percutaneous coronary intervention (PCI), early treatment with evolocumab as an addition to statin can lower low-density lipoprotein cholesterol (LDL-C) levels as well as reduce the incidence of recurrent ischemic cardiovascular events, while having satisfactory tolerability and safety, according to a study.
Special Reports
Galcanezumab Injection
Bilastine 10 mg orodispersible tablet
Esflurbiprofen 40 mg transdermal patch
Upadacitinib 15 mg XR-FC tab
Romosozumab 105 mg/1.17 mL soln for inj
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice, affecting millions of people globally. Stroke is one of its devastating complications, with the risk steeply increasing with advancing age. Additionally, AF is associated with more than a tripling of the risk of systemic embolic (SE) events. [J Am Heart Assoc 2020;9:e016724]
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
Conference Reports
Infection with the omicron variant of SARS-CoV-2 was less likely to result in hospitalization than infection with the delta variant, according to an observational study from Denmark presented at ECCMID 2022 and published in The Lancet.
Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.
SER-109, an investigational oral microbiome therapeutic, achieves superiority over placebo in reducing recurrent Clostridioides difficile infection (CDI) rates, according to updated findings from the phase III ECOSPOR-III trial.
Once-daily (QD) administration of low-dose elagolix 150 mg led to significantly reduced heavy menstrual bleeding (HMB) in premenopausal women with uterine fibroids, according to a study presented at ACOG 2022.
Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.
Patients with Parkinson’s disease dementia (PDD) who continued treatment with pimavanserin had a lower risk of psychosis relapse compared with those on placebo, according to a post hoc analysis of the HARMONY* trial presented at AAN 2022.
Combination therapy with relugolix (once daily relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) leads to improvement in heavy menstrual bleeding (HMB) and in other uterine fibroid (UF)-related symptoms independent of the location of the largest fibroid, results of a recent study have shown.
Multimedia
